Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Laura Tandeske

David Y Chien

Angelica Medina-Selby

Doris Guenzi Coit

Carlos George-Nascimento

Phillip M Arcangel

Sansan Lin

Phillip Arcangel

Carlos George-Nasciemento

David Ying Chien

Lin Sansan

Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.

HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof

The invention relates to a method of detecting HCV infection in a biological sample, the method comprising providing an immunoassay solid support, comprising an HCV anti-core antibody, an antigen comprising an HCV NS3/4epitope, and an HCV multiple epitope fusion antigen, that can detect both HCV antigens and antibodies present in a sample. The invention also includes polynucleotides encoding multiple epitope fusion antigens for use in the assay, recombinant vectors and host cells comprising such polynucleotides, and methods of producing the multiple epitope fusion antigens.

Polynucleotides encoding a multiple epitope fusion antigen for use in an HCV antigen/antibody combination assay

HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.

Immunoassays for anti-HCV antibodies

Multiple fusion antigens for use in immunoassays for anti-HCV antibodies

An HCV core antigen and NS3/4a antibody combination assay that can detect both HCV antigens and antibodies present in a sample using a single solid matrix, is provided, as well as immunoassay solid supports for use in the assay.

HCV antigen/antibody combination assay

Growing community of inventors

San Leandro, CA, United States of America

Laura Tandeske